Federation Des Caisses Desjardins Du Quebec Vaxcyte, Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $18.9 Billion
- Q3 2024
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 56 shares of PCVX stock, worth $4,750. This represents 0.0% of its overall portfolio holdings.
Number of Shares
56Holding current value
$4,750% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PCVX
# of Institutions
357Shares Held
123MCall Options Held
772KPut Options Held
430K-
Vanguard Group Inc Valley Forge, PA11.4MShares$970 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$927 Million0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$843 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$737 Million13.83% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.9MShares$416 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $5.03B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...